Sökning: "prostate-specific antigen"
Visar resultat 1 - 5 av 85 avhandlingar innehållade orden prostate-specific antigen.
1. Metabolism of free and complexed prostate - specific antigen and their utility for diagnosis and prognosis of prostate cancer
Sammanfattning : Prostate-specific antigen (PSA) is a glycoprotein produced by the prostate gland. It occurs in several molecular forms in the blood and assays have been developed to measure free PSA and PSA in complex with alpha-1-antichymotrypsin (PSA-ACT). LÄS MER
2. Impact of renal dysfunction on serum Prostate-Specific Antigen
Sammanfattning : Measurement of prostate-specific antigen (PSA) in blood is an important tool in detection for prostate cancer. PSA occurs in several molecular forms in blood: mainly as a free form with a molecular mass of 28 kDa; and as PSA complexed to alpha-1-antichymotrypsin, complexed PSA, with a molecular mass of 90 kDa. LÄS MER
3. Structure, evolution and expression of glandular kallikrein genes
Sammanfattning : Prostate-specific antigen (PSA) is a worldwide used tool for the diagnosis and monitoring of prostate cancer. It is a serine protease and belongs to the family of glandular kallikreins. Humans have three classical glandular kallikreins, but it has been reported that rodents have many more. LÄS MER
4. Biochemical Studies of Semenogelins with Emphasis on Zinc-Binding Properties
Sammanfattning : Semenogelins I and II (SgI and SgII) are homologous and rapidly evolving proteins that have a repetitive primary structure and are synthesized mainly in the seminal vesicles. Upon ejaculation, a gelatinous coagulum is formed when the semenogelin-rich secretion from the seminal vesicles is mixed with the prostate secretion, which contains high concentrations of zinc(II) and proteases. LÄS MER
5. Magnetic Resonance Imaging as a Screening Tool for Prostate Cancer
Sammanfattning : The overall aim of this thesis was to explore the role of Magnetic resonance imaging (MRI) of the prostate as an adjunct to the prostate-specific antigen (PSA)-test in screening for prostate cancer (PCa), focusing on the performance of MRI in detecting clinically significant PCa within the randomised controlled GÖTEBORG Prostate Cancer Screening 2 Trial. By inviting men 50–60 years of age to different screening strategies—PSA cut-off for biopsy 3. LÄS MER